Skip to main content
. Author manuscript; available in PMC: 2024 Jul 1.
Published in final edited form as: Pediatr Pulmonol. 2023 Apr 21;58(7):2042–2049. doi: 10.1002/ppul.26429

Table 1.

Study participant characteristics at baseline (n=299)

Variable Description N=299
Age Mean (SD) 8.5 (1.8)
Female, n (%) 142 (47.5%)
Race or ethnic group, n (%) Black 111 (37.1%)
Mixed 52 (17.4%)
Other 124 (41.5%)
White 12 (4.0%)
Hispanic, n (%) 104 (34.8%)
Household Income <$25,000, n (%) No 126 (42.1%)
Yes 128 (42.8%)
Unknown 45 (15.1%)
BMI Percentile Mean (SD) 74.6 (27.1)
BMI Category, n (%) Underweight 4 (1.3%)
Normal 150 (50.2%)
Overweight 39 (13.0%)
Obese 106 (35.5%)
Allergic Sensitization ≥ 1 allergen, n (%) 214 (71.6%)
ICS Controller Medication Use, n (%) 91 (30.4%)
F E NO (ppb) Mean (SD) 21.0 (22.5)
FEV1 % predicted Mean (SD) 101.1 (19.2)
FVC % predicted § Mean (SD) 100.0 (17.6)
FEV 1 /FVC Mean (SD) 0.9 (0.1)
Maximum asthma symptom-days # Mean (SD) 2.9 (4.1)

FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; FENO: fractional exhaled Nitric Oxide.

Maximum asthma symptom-days = in the 2 weeks prior to each follow-up survey, the greatest result of the following three variables: 1) number of days with wheezing, cough, or chest tightness, 2) number of days on which child had to slow down or discontinue play activities due to wheezing, chest tightness, or cough, 3) number of nights with wheezing, cough, or chest tightness leading to disturbed sleep due to child’s asthma

total n included (%): 95 (31.8%),

total n included (%): 261 (87.6%),

§

total n included (%): 261 (87.6%),

total n included (%): 261 (87.6%),

#

total n included (%): 284 (99.3%)